UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~August~~September 1521, 2023

ContraFect Corporation

(Exact name of registrant as specified in its charter)

Delaware

001-36577

39-2072586

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

28 Wells Avenue, 3rd Floor, Yonkers, New York 10701 ~~(Address of principal executive offices) (Zip Code)~~

(Address of principal executive offices) (Zip Code)

(914) 207-2300

Registrant’s telephone number, including area code

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		~~TradingSymbol~~Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CFRX		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on ~~July~~August 2115, 2023, ContraFect Corporation (the “Company”) was notified by the staff of The Nasdaq Stock Market (“Nasdaq”) that the Company ~~had~~did ~~regained~~not ~~compliance~~meet ~~with~~ the ~~$1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2) and the~~ minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Capital Market (the “Staff Determination”). The Company requested a hearing before a Nasdaq ~~also~~Hearings ~~notified~~Panel (“Panel”) to appeal the Staff Determination, which stayed the suspension of trading and delisting of the Company’s ~~that~~common itstock ~~would~~pending bethe ~~subject~~conclusion toof athe ~~one-year~~hearing ~~Mandatory~~process. There can be no assurance that the Panel ~~Monitor~~will ~~consistent~~grant ~~with~~the ~~Nasdaq~~Company’s ~~Listing~~request ~~Rule~~for ~~5815(d)(4)(B)~~continued listing on The Nasdaq Capital Market.

On ~~August~~September 1521, 2023, the ~~Nasdaq~~Company ~~staff~~was ~~(“Staff”)~~notified ~~informed~~by the ~~Company~~staff ~~that,~~of ~~based~~Nasdaq on (the ~~Company’s~~“Staff ~~Quarterly~~Deficiency ~~Report~~Letter”) onthat, ~~Form 10-Q~~ for the ~~quarterly~~last ~~period~~thirty ~~ended~~consecutive ~~June 30,~~business ~~2023~~days, the ~~Company~~bid ~~did~~price ~~not~~for ~~meet~~ the ~~Minimum Stockholders~~Company’s ~~Equity~~common ~~Requirement~~stock orhad ~~any~~closed ~~other~~below ~~alternatives~~the ~~available~~minimum $1.00 per share requirement for continued listing on ~~the~~The Nasdaq Capital Market ~~and~~under ~~therefore the Staff had determined to delist the Company’s common stock from the~~ Nasdaq ~~Capital~~Listing ~~Market~~Rule 5550(a)(2) (the “~~Staff~~Minimum ~~Determination~~Bid Price Requirement”). AsIn aaccordance ~~result~~with ofNasdaq ~~the~~Listing ~~Mandatory Panel Monitor described in the July~~Rule 215810(c)(3)(A), ~~2023 notice from Nasdaq,~~ the Company ishas ~~not~~been ~~eligible~~provided ~~for~~an ainitial ~~compliance~~ period toof ~~regain~~180 ~~compliance~~calendar ~~with~~days, ~~the~~or ~~Minimum~~until ~~Stockholders’~~March 19, ~~Equity Requirement~~2024, ~~which~~to ~~led~~regain tocompliance. The letter states that the ~~Staff~~Nasdaq ~~Determination.~~staff ~~The~~will ~~Staff~~provide ~~also~~written ~~informed~~notification that the Company ~~that,~~has ~~unless~~achieved ~~the~~compliance ~~Company~~with ~~requests~~Rule 5550(a)(2) if anat ~~appeal~~any oftime ~~the~~before ~~Staff~~March 19, ~~Determination~~2024, ~~trading~~the bid price of the Company’s common stock ~~will~~closes beat ~~suspended~~$1.00 atper ~~the~~share ~~opening~~or ofmore ~~business~~for ona ~~August 24,~~minimum ~~2023~~of ~~and~~ten aconsecutive ~~Form~~business ~~25-NSE~~days. ~~will~~The beStaff ~~filed~~Deficiency ~~with~~Letter ~~the~~has ~~Securities~~no ~~and~~immediate ~~Exchange~~effect ~~Commission~~on (the ~~“SEC”),~~listing ~~which~~or ~~would~~trading ~~remove~~of the Company’s ~~securities~~common ~~from listing and registration on the Nasdaq Capital Market~~stock.

~~The~~If the Company ~~intends~~does tonot ~~request~~regain acompliance ~~hearing~~with ~~before~~the aMinimum ~~Nasdaq~~Bid ~~Hearings~~Price ~~Panel~~Requirement by ~~(“Panel”)~~March 19, to2024, ~~appeal~~ the ~~Staff~~Company ~~Determination~~may be eligible for an additional 180 calendar day compliance period. To ~~The~~qualify, the Company’s ~~hearing~~would ~~request~~be isrequired ~~expected~~ to ~~stay~~meet the ~~suspension~~continued listing requirement for market value of ~~trading~~publicly held shares and ~~delisting~~all other initial listing standards for The Nasdaq Capital Market, with the exception of the ~~Company’s~~Minimum ~~common~~Bid ~~stock~~Price ~~pending~~Requirement, ~~the~~and ~~conclusion~~would need to provide written notice of its intention to cure the ~~hearing~~deficiency ~~process.~~during ~~Consequently~~the second compliance period, for example, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that the Company’s ~~common~~will ~~stock~~not isbe ~~expected~~able to ~~remain~~cure ~~listed~~the ondeficiency, or if the Company is otherwise not eligible, Nasdaq ~~Capital~~would ~~Market~~notify atthe ~~least~~Company ~~until~~that its securities would be subject to delisting. In the ~~Panel~~event ~~renders~~of such a ~~decision~~notification, ~~following~~the Company may appeal the ~~hearing~~Nasdaq staff’s determination to delist its securities. There can be no assurance that the ~~Panel~~Company will be eligible for the additional 180 calendar day compliance period, if applicable, or that the Nasdaq staff would grant the Company’s request for continued listing onsubsequent ~~The~~to ~~Nasdaq~~any ~~Capital~~additional ~~Market~~delisting notification.

The Company continues to evaluate various alternative courses of action to regain compliance with the Minimum Stockholders’ Equity Requirement and the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to maintain compliance with the Nasdaq Capital Market’s continued listing requirements or regain compliance with the Minimum Stockholders’ Equity Requirement or the Minimum Bid Price Requirement.

Forward-Looking Statements

This ~~current~~Current ~~report~~Report on Form 8-K (“Form 8-K”) contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this ~~current~~Form ~~report~~8-K include, without limitation, statements regarding the Company’s intent or ability to regain compliance with the Minimum Stockholders’ Equity Requirement, ~~the~~and ~~Company’s intention to appeal~~ the ~~Staff~~Minimum ~~Determination,~~Bid ~~the~~Price ~~Company’s expectation that a request for a Panel hearing would stay delisting of its common stock pending the conclusion of the hearing process~~Requirement, the outcome of the Panel’s review of any Company appeal of the Staff Determination, and any courses of action to regain compliance with the Nasdaq Capital Market’s continued listing requirements. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, there can be no assurance that the Company will meet the Minimum Stockholders’ Equity Requirement and the Minimum Bid Price Requirement in the future or otherwise meet Nasdaq compliance standards; that Nasdaq will grant the Company any relief from delisting or whether the Company can agree to or ultimately meet applicable Nasdaq requirements for any such relief; that the Company has and expects to continue to incur significant losses; the Company’s need for additional funding, which may not be available on reasonable terms or at all; the occurrence of any adverse events related to the discovery, development and commercialization of the Company’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, lack of regulatory approval, or unsuccessful attainment or maintenance of patent protection; and the other important factors described under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2023, and its other filings with the SEC. Any forward-looking statement made by the Company in this current report is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Report on Form 10-Q for the quarterly period ended June 30, 2023, filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2023, and its other filings with the SEC. Any forward-looking statement made by the Company in this Form 8-K is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CONTRAFECT CORPORATION
Date: August 18, 2023	By:	/s/ Michael Messinger
Date: September 29, 2023	By:	/s/ Natalie Bogdanos
		Michael Messinger
		Natalie Bogdanos
		Chief Financial Officer
		General Counsel & Corporate Secretary

Filing Compare · CONTRAFECT Corp